Inventor
MATSUO MASAFUMI
JP15 patents
⚠️ This page may combine multiple inventors who share the name “MATSUO MASAFUMI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
DAIICHI SANKYO CO LTD
3 patentsUS9657050B2May 23, 2017
ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
DAIICHI SANKYO CO LTD31 citations97
US9243026B2Jan 26, 2016
ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
DAIICHI SANKYO CO LTD5 citations83
US11958878B2Apr 16, 2024
Therapeutic agent for glycogen storage disease type IA
DAIICHI SANKYO CO LTD1 citations60
JAPAN CHEM RES
3 patentsUS6653466B2Nov 25, 2003
Pharmaceutical composition for treatment of duchenne muscular dystrophy
JAPAN CHEM RES132 citations97
US6727355B2Apr 27, 2004
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
JAPAN CHEM RES152 citations95
US6548284B1Apr 15, 2003
Membrane-bound metalloprotease and soluble secreted form thereof
JAPAN CHEM RES3 citations53
MATSUO MASAFUMI
3 patentsUS9657049B2May 23, 2017
ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
MATSUO MASAFUMI31 citations96
US8624019B2Jan 7, 2014
ENA nucleic acid drugs modifying splicing in mRNA precursor
MATSUO MASAFUMI38 citations96
US8719650B2May 6, 2014
Self-diagnosis system and test circuit determination method
MATSUO MASAFUMI1 citations50
KNC LABORATORIES CO LTD
2 patentsUS12202869B2Jan 21, 2025
Inhibition of myostatin signal by myostatin splice variant-derived protein and utilization thereof
KNC LABORATORIES CO LTD0 citations52
US10174319B2Jan 8, 2019
Nucleic acid drug for inducing skipping of variant exon of CD44 gene and increasing expression of normal type CD44 mRNA
KNC LABORATORIES CO LTD0 citations47